Abo Bibliothek: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0731-8898

ISSN Online: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Effects of Tobacco on Biochemical Parameters in Healthy and Type 2 Diabetic Subjects

Volumen 39, Ausgabe 1, 2020, pp. 23-37
DOI: 10.1615/JEnvironPatholToxicolOncol.2020031383
Get accessGet access

ABSTRAKT

Diabetes and tobacco use are two of the largest public health challenges of our time. We aim to investigate the association between the two by comparing biochemical profiles of diabetic tobacco users (TUs) and tobacco nonus-ers (TNUs) to provide insight into the joint effect of tobacco and diabetes on body systems. This case-controlled study included 265 subjects, aged 18-60 yr, from the suburban population of Delhi, India. With the help of a questionnaire, participants are interviewed regarding their history of tobacco use. Results show association of tobacco use with elevated body-mass index, blood glucose levels, and insulin resistance in otherwise healthy and diabetic TUs. Even without previous history of coronary heart disease, total cholesterol and triglycerides are significantly further increased in TUs rather than in TNUs, indicative of initiation of lipid metabolism disorders. Tobacco use is also seen as a cause of oxidant/antioxidant imbalance in the body. Low serum albumin coupled with increased markers of inflammation and globulin levels is an indicator of generalized inflammation caused by tobacco's toxic effects. Creatinine levels are significantly higher in diabetic TUs, posing a threat to nephropathy progression. Evidence sufficiently infers that tobacco activates multiple biological pathways, through which the risk of metabolic disease increases. These factors may work in conjunction to increase risk of certain microvascular and macrovascular complications.

REFERENZEN
  1. Piemonte L. Type 2 diabetes [monograph on the Internet]. Brussels, Belgium: International Diabetes Federation; 2019 [cited 2019 May 25]. Available from: https://idf. org/52-about-diabetes.html.

  2. World Health Organization. Global report on diabetes. 2016. [cited 2020 March 5]. Available from: https:// apps.who.int/iris/bitstream/handle/10665/204871/ 9789241565257_eng.pdf;jsessionid=053A4D10DE- 29CAC8277D7343AC78C75D?sequence=1.

  3. Akter S, Rahman MM, Abe SK, Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. Bull World Health Organ. 2014;92(3):204-13A.

  4. Prasad S, Cucullo L. Impact of tobacco smoking and type-2 diabetes mellitus on public health: a cerebrovascular perspective. J Pharmacovigil. 2015 Nov;Suppl 2:e003.

  5. National Center for Chronic Disease Prevention and Health Promotion. The health consequences of smoking-50 years of progress. A report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US); 2014.

  6. National Center for Chronic Disease Prevention, Health Promotion. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US); 2010.

  7. Sharma P, Murthy P, Shivhare P. Nicotine quantity and packaging disclosure in smoked and smokeless tobacco products in India. Indian J Pharmacol. 2015 Jul-Aug; 47(4):440-3.

  8. Watanabe N, Fukushima M, Taniguchi A, Okumura T, Nomura Y, Nishimura F, Aoyama S, Yabe D, Izumi Y, Ohtsubo R, Nakai Y, Nagasaka S. Smoking, white blood cell counts, and TNF system activity in Japanese male subjects with normal glucose tolerance. Tob Induc Dis. 2011 Nov 25;9(1):12.

  9. American Diabetes Association. Standards of medical care in diabetes, with notable new recommendations for people with cardiovascular disease and diabetes [monograph on the Internet]. Arlington, VA: American Diabetes Association; 2017. Available from: http://www.diabetes. org/newsroom/press-releases/2017/american-diabetes-association-2018-release-standards-of-medical-care-in-diabetes.html.

  10. World Health Organization. Measuring change in nutritional status [monograph on the Internet]. Geneva, Switzerland: World Health Organization; 1982.

  11. World Health Organization. WHO Expert consultation on waist circumference (WC) and waist-hip ratio (WHR) [monograph on the Internet]. Geneva, Switzerland: World Health Organization; 2008. p. 8-11.

  12. World Health Organization. Physical status: the use and interpretation of anthropometry. Technical report series no. 854. Geneva, Switzerland: World Health Organization; 1995.

  13. Grimes DS, Goddard J. Effect of cigarette smoking on gastric emptying. Br Med J. 1978 Aug 12;2(6135):460-1.

  14. Xie X-T, Liu Q, Wu J, Wakui M. Impact of cigarette smoking in type 2 diabetes development. Acta Pharmacol Sin. 2009 June;30(6):784-7.

  15. Bruin JE, Gerstein HC, Morrison KM, Holloway AC. Increased pancreatic ft-cell apoptosis following fetal and neonatal exposure to nicotine is mediated via the mito-chondria. Toxicol Sci. 2008 Jun;103(2):362-70.

  16. Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin Jam Soc Nephrol. 2008;3(1):226-36.

  17. Nagasawa Y, Yamamoto R, Rakugi H, Isaka Y. Cigarette smoking and chronic kidney diseases. Hypertens Res. 2012;35(3):261-5.

  18. Mittal A, Sathian B, Kumar A, Chandrasekharan N, Sunka AJ. Diabetes mellitus as a potential risk factor for renal disease among Nepalese: a hospital-based case-control study. Nepal J Epidemiol. 2010;1Q):22-5.

  19. Venugopal S, Iyer UM. Risk factor analysis and prevalence of microalbuminuria among type 2 diabetes mellitus subjects: the need for screening and monitoring microalbumin. Asian J Exp Biol Sci. 2010;1(3):652-9.

  20. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int. 2000 May;57(5):2072-9.

  21. Ohkuma T, Nakamura U, Iwase M, Ide H, Fujii H, Jodai T, Kaizu S, Kikuchi Y, Idewaki Y, Sumi A, Hirakawa Y, Kitazono T. Effects of smoking and its cessation on creatinine- and cystatin C-based estimated glomerular filtration rates and albuminuria in male patients with type 2 diabetes mellitus: the Fukuoka diabetes registry. Hypertens Res. 2016 Oct;39(10):744-51.

  22. Nazki F, Syyeda A, Mohammed S. Total proteins, albumin and HBA1c in type 2 diabetes mellitus. Medpulse Int J Biochem. 2017;3(3):40-2.

  23. Gossett LK, Johnson HM, Piper ME, Fiore MC, Baker TB. Smoking intensity and lipoprotein abnormalities in active smokers. J Clin Lipidol. 2009;3(6):372-8.

  24. Campbell SC, Moffatt RJ, Stamford B. Smoking and smoking cessation-the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis. 2008;201(2):225-35.

  25. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989 Mar 25;298(6676):784-8.

  26. Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J. 2011;161(1):145-51.

  27. Austin MA. Plasma triglyceride and coronary heart disease. Atheroscler Throm. 1991;11(1):2-14.

  28. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-7.

  29. Muscat JE, Harris RE, Haley NJ, Wynder EL. Cigarette smoking and plasma cholesterol. Am Heart J. 1991;121(1): 141-7.

  30. Fagerstrom K. The epidemiology of smoking. Drugs. 2002;62(2):1-9.

  31. Simons L, Simons J, Jones A. The interactions of body weight, age, cigarette smoking and hormone usage with blood pressure and plasma lipids in an Australian community. Aust NZ J Med. 1984;14(3):215-21.

  32. Wynder E, Harris R, Haley NJ. Population screening for plasma cholesterol: community-based results from Connecticut. Am Heart J. 1989;117(3):649-56.

  33. Pagan K, Hou J, Goldenberg RL, Cliver SP, Tamura T. Effect of smoking on serum concentrations of total homocysteine and B vitamins in mid-pregnancy. Clin Chim Acta. 2001;306(1-2):103-9.

  34. McCarty M. Increased homocysteine associated with smoking, chronic inflammation, and ageing may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypoth. 2000;55(4):289-93.

  35. Austin R, Lentz S, Werstuck GJ. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11(S1):S56.

  36. Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, Yang F, Durante W, Chan L, Schafer AI, Pownall HJ. Hyper-homocysteinemia decreases circulating high-density lipo-protein by inhibiting apolipoprotein AI protein synthesis and enhancing HDL cholesterol clearance. Circ Res. 2006;99(6):598-606.

  37. Cheung BM, Wat NM, Man YB, Tam S, Cheng CH, Leung GM, Woo J, Janus ED, Lau CP, Lam TH, Lam KS. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong cardiovascular risk factor prevalence study-2 (CRISPS2). Am J Hyper. 2008;21(1):17-22.

  38. Nakayama Y, Komuro R, Yamamoto A, Miyata Y, Tanaka M, Matsuda M, Fukuhara A, Shimomura I. RhoA induces expression of inflammatory cytokine in adipocytes. Biochem Biophys Res Comm. 2009;379(2):288-92.

  39. Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytok Network. 2006;17(1):4-12.

  40. Mohammadi M, Gozashti MH, Aghadavood M, Mehdizadeh MR, Hayatbakhsh MM. Clinical significance of serum IL-6 and TNF-a levels in patients with metabolic syndrome. Rep Biochem Mol Biol. 2017;6(1):74.

  41. Camkurt MA, Findikli E, Bakacak M, Karaaslan MF, Tolun Fl, Tuman TC. Depression in pregnancy is associated with decreased glutathione peroxidase activity in fetal cord blood. J Psych Res. 2016;79:57-60.

  42. Burke A, FitzGerald GA. Oxidative stress and smoking-induced vascular injury. Progr Cardio Dis. 2003; 46(1):79-90.

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain